Data and code from: Hydrogen-rich jelly exhibits a positive effect on heart rate variability during orthostatic loading in healthy adults: A randomized crossover trial
Data files
Sep 08, 2026 version files 113.90 KB
-
Analysis_for_primary_endpoint_English.sas
4.04 KB
-
Baseline_characteristics_English.sas
14.82 KB
-
Calculation_Cohens_d_English.sas
7.27 KB
-
HRV_Data_English.xlsx
39.85 KB
-
MACRO_English.sas
22.71 KB
-
Participant_Baseline_Data_English.xlsx
10.51 KB
-
README.md
5.34 KB
-
Subgroup_analysis_English.sas
9.35 KB
Abstract
Hydrogen gas has been shown to improve quality of life by enhancing mood, stress responsiveness, and autonomic regulation. The effects of hydrogen-rich jelly (HRJ) on autonomic responses during postural transition remain unclear. This double-blind, randomized, placebo-controlled crossover trial aimed to investigate the effects of HRJ on heart rate variability (HRV) indices in 50 healthy adults (mean age, 44.2 ± 11.3 years). HRJ (30-40 ppm, 10 g) or placebo jelly was orally administered 24 h, 1.5 h, and immediately before testing. HRV was continuously recorded during an orthostatic loading protocol consisting of four sequential 1min phases: rest (seated baseline), stand-up (immediately after transitioning to standing), standing (sustained upright posture), and resitting (immediately after returning to sitting). We measured the coefficient of variation of the R-R interval (CVRR), low-frequency, high-frequency, and low-frequency-to-high-frequency (L/H) ratio components. Values for each posture were adjusted based on those at rest. Among the 48 participants with complete data under both conditions, HRJ intake resulted in a significantly lower CVRR during the stand-up phase (mean difference, -0.46; p = 0.047) and a significantly lower L/H ratio during the resitting phase (mean difference, -1.51; p = 0.027). No significant differences were observed between the rest and standing phases. Our study suggests that HRJ intake modulates autonomic fluctuations during postural transitions.
Dataset DOI: 10.5061/dryad.7h44j1091
Data description
This dataset was generated for a double-blind, randomized, placebo-controlled crossover trial evaluating the acute effects of hydrogen-rich jelly compared with placebo jelly on heart rate variability during orthostatic loading in healthy adults. Participants completed orthostatic testing under both conditions, and electrocardiography-derived heart rate variability indices were calculated during predefined 1-min phases, including seated rest, standing-up, standing, and re-sitting.
The dataset contains de-identified participant-level data and SAS analysis programs used to generate the baseline characteristics, primary endpoint analysis, exploratory subgroup analyses, and effect-size calculations reported in the associated manuscript. No directly identifying personal information is included. Empty cells/empty colored cells represent missing data.
Abbreviations and codes
HRV: heart rate variability
HRJ: hydrogen-rich jelly
ECG: electrocardiography
SAS: Statistical Analysis System
The intervention conditions represent hydrogen-rich jelly and placebo jelly. Orthostatic testing phases include seated rest, standing up, standing, and re-sitting.
Files and variables
HRV_Data_English.xlsx
This file contains the de-identified heart rate variability dataset used for the main statistical analyses. The data include participant-level measurements obtained under the hydrogen-rich jelly and placebo conditions during predefined orthostatic testing phases.
Participant_Baseline_Data_English.xlsx
This file contains de-identified participant-level baseline data used to summarize participant characteristics in the study. The file includes demographic and baseline physiological variables used for descriptive analyses.
Analysis_for_primary_endpoint_English.sas
This SAS program was used to perform the primary endpoint analysis for the study.
Baseline_characteristics_English.sas
This SAS program was used to generate the baseline characteristics table.
Calculation_Cohens_d_English.sas
This SAS program was used to calculate Cohen’s d effect sizes for the relevant comparisons.
Subgroup_analysis_English.sas
This SAS program was used to perform the exploratory subgroup analyses reported in the associated manuscript or supplementary analyses.
MACRO_English.sas
This SAS macro file contains reusable SAS macro code used by the analysis programs.
Code/software
The data files, HRV_Data_English.xlsx and Participant_Baseline_Data_English.xlsx, can be viewed using standard spreadsheet software, including Microsoft Excel, LibreOffice Calc, or other software capable of opening .xlsx files. The SAS program files (.sas) are plain-text files and can be viewed using any text editor.
The statistical analyses were conducted using SAS software. The included SAS programs operate on SAS datasets assigned to the MYLIB library and do not directly import the deposited Excel files. Before running the programs, users must update the MYLIB directory path and prepare the corresponding SAS datasets using the variable and dataset names referenced in the programs.
MACRO_English.sas should be run before the analysis programs that use its macros and formats. The remaining programs document the statistical procedures used to generate the baseline characteristics, primary endpoint analyses, effect-size calculations, and exploratory subgroup analyses.
The deposited Excel files contain the de-identified participant-level source data. However, because the original data-import and preprocessing program used to convert the Excel files into the analysis-ready SAS datasets is not included, complete end-to-end reproduction directly from the deposited Excel files may require additional data preparation.
The files can nevertheless be inspected using freely available spreadsheet and text-editing software. SAS software is required to execute the deposited analysis programs.
Access information
The data and code will be made publicly available through this Dryad dataset upon publication. No additional publicly accessible locations for these data are currently available.
The dataset was generated from the authors’ own randomized crossover trial and was not derived from any third-party dataset. Therefore, no external data-source licenses apply.
No directly identifying personal information is included in the dataset. No additional access restrictions apply to the de-identified data and analysis code provided in this repository.
Human subjects data
All participants provided informed consent for the publication of de-identified research data in a public repository. Before deposition, all direct identifiers were removed, and the original study codes were replaced with anonymous participant IDs that cannot be linked to individuals by data users. Dates, contact information, medical record numbers, and other personally identifiable information were not included. Demographic and physiological variables were minimized and prepared in accordance with the approved ethics protocol and applicable legal and ethical guidelines.